The 2014 edition of MSAA’s MS Research Update is a comprehensive overview of the latest research findings on the FDA-approved disease-modifying therapies, as well as many e,perimental treatments. This update features ground-breaking studies not only with medications, but also in areas such as stem-cell research, therapies for myelin repair and protection, biomarkers, genetic studies, and more.
In addition to the e,citing research aimed at relapsing forms of MS, a number of studies are also looking into the treatment of progressive forms of MS. To assist individuals interested in learning more, studies involving progressive MS have been highlighted.
Highlights from The Consortium of Multiple Sclerosis Centers’ Annual Meeting
MSAA has posted a new online article giving highlights from this year’s Consortium of Multiple Sclerosis Centers’ Annual Meeting. MS experts from around the country attended this exciting conference, where the latest findings in MS research, treatments, symptom management, and patient care were presented.
Topics highlighted in this article include three new drugs presently under review by the FDA (teriflunomide, dimethyl fumarate, and alemtuzumab), while also giving the results of the Copaxone® study with lower-frequency dosing. The article explains the difficulties in understanding progressive forms of MS, presents the findings through different types of brain imaging, and provides information about a new study. Biomarkers, surrogates, and cognition are addressed in detail as well.